186 related articles for article (PubMed ID: 24560949)
1. Intercalation of antitumor drug doxorubicin and its analogue by DNA duplex: structural features and biological implications.
Agudelo D; Bourassa P; Bérubé G; Tajmir-Riahi HA
Int J Biol Macromol; 2014 May; 66():144-50. PubMed ID: 24560949
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation of antitumor drug Doxorubicin and its analogue by chitosan nanoparticles.
Sanyakamdhorn S; Agudelo D; Tajmir-Riahi HA
Biomacromolecules; 2013 Feb; 14(2):557-63. PubMed ID: 23305154
[TBL] [Abstract][Full Text] [Related]
3. tRNA binding to antitumor drug doxorubicin and its analogue.
Agudelo D; Bourassa P; Beauregard M; Bérubé G; Tajmir-Riahi HA
PLoS One; 2013; 8(7):e69248. PubMed ID: 23922696
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic doxorubicin and its derivative bind milk β-lactoglobulin.
Agudelo D; Beauregard M; Bérubé G; Tajmir-Riahi HA
J Photochem Photobiol B; 2012 Dec; 117():185-92. PubMed ID: 23147200
[TBL] [Abstract][Full Text] [Related]
5. Review on the binding of anticancer drug doxorubicin with DNA and tRNA: Structural models and antitumor activity.
Agudelo D; Bourassa P; Bérubé G; Tajmir-Riahi HA
J Photochem Photobiol B; 2016 May; 158():274-9. PubMed ID: 26971631
[TBL] [Abstract][Full Text] [Related]
6. Nanopore single-molecule analysis of DNA-doxorubicin interactions.
Yao F; Duan J; Wang Y; Zhang Y; Guo Y; Guo H; Kang X
Anal Chem; 2015 Jan; 87(1):338-42. PubMed ID: 25493921
[TBL] [Abstract][Full Text] [Related]
7. Probing the binding sites of antibiotic drugs doxorubicin and N-(trifluoroacetyl) doxorubicin with human and bovine serum albumins.
Agudelo D; Bourassa P; Bruneau J; Bérubé G; Asselin E; Tajmir-Riahi HA
PLoS One; 2012; 7(8):e43814. PubMed ID: 22937101
[TBL] [Abstract][Full Text] [Related]
8. Solution conformation of the (-)-cis-anti-benzo[a]pyrenyl-dG adduct opposite dC in a DNA duplex: intercalation of the covalently attached BP ring into the helix with base displacement of the modified deoxyguanosine into the major groove.
Cosman M; Hingerty BE; Luneva N; Amin S; Geacintov NE; Broyde S; Patel DJ
Biochemistry; 1996 Jul; 35(30):9850-63. PubMed ID: 8703959
[TBL] [Abstract][Full Text] [Related]
9. Influence of aglycone modifications on the binding of anthracycline drugs to DNA: the molecular structure of idarubicin and 4-O-demethyl-11-deoxydoxorubicin complexed to d(CGATCG).
Gao YG; Wang AH
Anticancer Drug Des; 1991 Jul; 6(3):137-49. PubMed ID: 1872945
[TBL] [Abstract][Full Text] [Related]
10. Identification and hydropathic characterization of structural features affecting sequence specificity for doxorubicin intercalation into DNA double-stranded polynucleotides.
Kellogg GE; Scarsdale JN; Fornari FA
Nucleic Acids Res; 1998 Oct; 26(20):4721-32. PubMed ID: 9753742
[TBL] [Abstract][Full Text] [Related]
11. Applications of chitosan nanoparticles in drug delivery.
Tajmir-Riahi HA; Nafisi Sh; Sanyakamdhorn S; Agudelo D; Chanphai P
Methods Mol Biol; 2014; 1141():165-84. PubMed ID: 24567139
[TBL] [Abstract][Full Text] [Related]
12. Interaction of antioxidant flavonoids with tRNA: intercalation or external binding and comparison with flavonoid-DNA adducts.
Kanakis CD; Tarantilis PA; Polissiou MG; Tajmir-Riahi HA
DNA Cell Biol; 2006 Feb; 25(2):116-23. PubMed ID: 16460235
[TBL] [Abstract][Full Text] [Related]
13. Structural modeling for DNA binding to antioxidants resveratrol, genistein and curcumin.
N'soukpoé-Kossi CN; Bourassa P; Mandeville JS; Bekale L; Tajmir-Riahi HA
J Photochem Photobiol B; 2015 Oct; 151():69-75. PubMed ID: 26188387
[TBL] [Abstract][Full Text] [Related]
14. Solution structural study of a DNA duplex containing the guanine-N7 adduct formed by a cytotoxic platinum-acridine hybrid agent.
Baruah H; Wright MW; Bierbach U
Biochemistry; 2005 Apr; 44(16):6059-70. PubMed ID: 15835895
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the topoisomerase II poison 9-amino-[N-(2-dimethylamino)ethyl]acridine-4-carboxamide bound to the DNA hexanucleotide d(CGTACG)2.
Adams A; Guss JM; Collyer CA; Denny WA; Wakelin LP
Biochemistry; 1999 Jul; 38(29):9221-33. PubMed ID: 10413496
[TBL] [Abstract][Full Text] [Related]
16. Poly(ethyleneglycol)-b-poly(ε-caprolactone-co-γ-hydroxyl-ε- caprolactone) bearing pendant hydroxyl groups as nanocarriers for doxorubicin delivery.
Chang L; Deng L; Wang W; Lv Z; Hu F; Dong A; Zhang J
Biomacromolecules; 2012 Oct; 13(10):3301-10. PubMed ID: 22931197
[TBL] [Abstract][Full Text] [Related]
17. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
Amin M; Badiee A; Jaafari MR
Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663
[TBL] [Abstract][Full Text] [Related]
18. Structural analysis of doxorubicin-polymer conjugates.
Sanyakamdhorn S; Bekale L; Agudelo D; Tajmir-Riahi HA
Colloids Surf B Biointerfaces; 2015 Nov; 135():175-182. PubMed ID: 26255162
[TBL] [Abstract][Full Text] [Related]
19. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the drug binding properties and cytotoxicity of DNA-capped nanoparticles designed as delivery vehicles for the anticancer agents doxorubicin and actinomycin D.
Alexander CM; Dabrowiak JC; Maye MM
Bioconjug Chem; 2012 Oct; 23(10):2061-70. PubMed ID: 23043330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
